Poor Sleep Tied to Greater Pain Interference in Early RA
METHODOLOGY:
Researchers analyzed data from the Canadian Early Arthritis Cohort study between 2016 and 2023 to examine the association between sleep disturbances and pain interference with daily functioning in patients with early RA.
They included 502 patients (mean age, 56 years; 68% women; mean duration of disease, 5.4 months) who presented with joint symptoms for a maximum duration of 12 months.
Participants completed Patient-Reported Outcomes Measurement Information System measures at baseline and at subsequent follow-ups to assess sleep disturbance and pain interference they experienced over the past 7 days.
The sleep disturbance domain included questions regarding perceptions of sleep quality, depth, and restoration, and the pain interference domain included questions about how pain affected physical, mental, and social functioning.
TAKEAWAY:
At baseline, 80% and 44% of patients with early RA reported having mild to severe scores for pain interference and sleep disturbance, respectively.
Those who reported higher sleep disturbance reported greater subsequent pain interference at the 6-month follow-up, even after adjusting for covariates (adjusted β coefficient, 0.76; 95% CI, 0.44-1.09).
These findings were consistent across several sensitivity analyses, including adjustments for time-varying symptoms of depression and concurrent pain interference at baseline.
IN PRACTICE:
'Identification and early intervention in problematic sleep patterns may contribute to enhanced long-term pain outcomes,' the authors wrote.
SOURCE:
This study was led by Burcu Aydemir, PhD, Northwestern University Feinberg School of Medicine, Chicago. It was published online on May 12, 2025, in Arthritis Care and Research .
LIMITATIONS:
This study relied on patient-reported assessments for sleep and pain interference, which may have introduced bias. Although the study accounted for several important confounders, it likely did not eliminate all potential sources of bias from unmeasured confounding. Additionally, the study did not assess the impact of the duration of sleep disturbances, so it's unclear how persistent or temporary sleep issues can affect pain interference outcomes.
DISCLOSURES:
The Canadian Arthritis Cohort study received funding from Pfizer, AbbVie, Hoffman La Roche, and other sources. Some authors reported receiving research support, grants, consulting fees, payments, or honoraria from; holding stocks of; or having other ties with various sources, including the funding agencies.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
24 minutes ago
- Medscape
Surgery vs Radiation in Early Glottic Cancer
TOPLINE: In a study of patients with T1 glottic squamous cell carcinomas, a group who received transoral microlaryngeal surgery alone had a higher risk for recurrence than a group who received radiotherapy alone, while 5-year overall survival rates remained similar between the two groups. Patients with T1b tumors had lower survival rates and higher rates of laryngectomy than those with T1a tumors. METHODOLOGY: Radiotherapy is the standard treatment for T1 glottic squamous cell carcinomas, but microlaryngeal surgery has emerged as an alternative, prompting researchers to assess their comparative effectiveness. This retrospective observational study included data of 777 patients (12% women; median age, 69 years) with T1a (n = 652) and T1b glottic squamous cell carcinomas (n = 125) from the Swedish Head and Neck Cancer Register, who were treated between 2008 and 2019. Overall, 367 patients (47.2%) underwent microlaryngeal surgery alone, 382 (49.2%) received radiotherapy as a single-modality treatment, while 28 (3.6%) received both treatments. Study outcomes were 5-year overall survival and risk for recurrence (defined as reappearance more than 6 months after diagnosis) or laryngectomy. TAKEAWAY: Overall survival at 5 years was higher in patients with T1a tumors than in those with T1b tumors (78.5% vs 66.2%; P = .005). Compared with radiotherapy alone, microlaryngeal surgery alone showed no significant difference in 5-year overall survival among patients with T1a (79.8% vs 77.5%; P = .53) and T1b (63.8% vs 65.9%; P = .610) tumors. The 5-year survival rate was 72.7% in patients who received both surgery and radiotherapy (all T1a), which was not significantly different from what was seen for those who received radiotherapy alone. Most recurrences (80% for T1a and 91% for T1b; 90.5% local) occurred within 3 years, with median times to recurrence of 17.9 months (T1a) and 15 months (T1b). At 3 years, recurrence rates were significantly higher after surgery alone than radiotherapy alone — 19.0% vs 6.4% for T1a tumors, and 56% vs 10% for T1b tumors (P < .001 for both comparisons). The 3-year cumulative incidence of laryngectomy was significantly higher in the T1b vs T1a group (P = .01). Laryngectomy occurred in 5.0% and 5.2% of patients with T1a tumors after surgery alone and radiotherapy alone, respectively, compared with 16.0% and 10.6% among patients with T1b tumors. IN PRACTICE: 'The results indicated a significant difference in 5‐year overall survival in favor of T1a vs T1b tumors and that microlaryngeal surgery should be used with caution in patients who have T1b cancer,' the authors wrote. SOURCE: The study was led by Hedda Haugen Cange, MD, PhD, Sahlgrenska University Hospital, Goteborg, Sweden. It was published online on June 26, 2025, in Cancer. LIMITATIONS: The study was limited by its retrospective, observational design. Data were missing on factors like voice quality, quality of life, and comorbidities, which limited comprehensive assessment. Additionally, the small sample size for T1b tumors reduced the study's statistical power. DISCLOSURES: The study was funded by Laryngfonden. One author reported serving on a Merck Sharp and Dohme End Point Review Committee outside the submitted work. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Washington Post
an hour ago
- Washington Post
Massachusetts advocates fear Trump's bill will unravel health safety net in Obamacare's model state
BOSTON — In the state that served as the model for Obamacare , advocates and health care workers fear the Trump administration is trying to dismantle piece-by-piece a popular program that has provided insurance, preventive care and life-saving medication to hundreds of thousands of people. Provisions contained in both the Senate and House versions of the massive tax and spending cuts bill advancing in Congress — a centerpiece of President Donald Trump's agenda — could strip health insurance from up to a quarter of the roughly 400,000 people enrolled in the Massachusetts Health Connector, according to state estimates.
Bloomberg
an hour ago
- Bloomberg
Novartis Blockbuster Antibody Drug Fails in Late-Stage Trial
Novartis AG 's drug Cosentyx failed in a late-stage study of patients suffering from inflammation in their blood vessels, a blow to the Swiss company's efforts to find new uses for the blockbuster medicine. The therapy, already one of Novartis's top sellers, did not demonstrate statistically significant improvement in adult patients suffering from giant cell arteritis, an ailment that can cause loss of vision and life-threatening aneurysms, according to a statement Thursday. The drug was compared with placebo, with all trial participants also getting a steroid.
